Glucotrack completes 1:20 reverse stock split; first human CBGM study successful with no serious adverse events

Glucotrack, Inc.

Effective Feb 3, 2025, every 20 pre-split shares combined into 1 share; outstanding shares reduced from ~155.5M to ~7.8M.
First in-human CBGM study met primary endpoint: no procedure- or device-related serious adverse events from implant through 7 days post-removal.
Six participants with diabetes mellitus; CBGM sensor lead placed intravascularly in subclavian vein for 4-day in-hospital monitoring.
Study confirmed CBGM sensor lead function; system accuracy consistent with prior animal studies; next step is long-term clinical trials.
Ticker GCTK unchanged; new CUSIP 45824Q705; shares trade on split-adjusted basis from Feb 4, 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Glucotrack, Inc.: Filed Certificate of Amendment to effect a one-for-twenty reverse stock split, effective February 3, 2025 (effective 2025-02-03).

Change: charter amendment
Effective: 2025-02-03

Exact text from the filing

filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Certificate of Amendment”), which became effective at 4:30 p.m. on February 3, 2025

View on SEC.gov

8 governance changes filed in the last 30 days. Browse all governance changes →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-004793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.